Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chiasma Inc (Chiasma) is a clinical-stage bio pharmaceutical company. The company involves in development of oral medications for the treatment of rare and serious chronic diseases. It develops oral medications through its transient permeability enhancer (TPE) technology platform, which is designed to enable the development of oral forms of therapies. It clinical product candidate includes oral octreotide capsules, a novel formulation of octreotide which is in Phase 3 clinical trials intended for the treatment of adult patients with acromegaly. The company has operations in the US and Israel. Chiasma is headquartered in Waltham, Massachusetts, the US.
Products and Services
| Products |
|---|
| Pipeline |
| Oral Octreotide Capsules |
Competitor Comparison
| Key Parameters | Chiasma Inc | Camurus AB | OptiNose Inc | Fortovia Therapeutics Inc (Inactive) | Ipsen Biopharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Sweden | United States of America | United States of America | United States of America |
| City | Needham | Lund | Yardley | Raleigh | Cambridge |
| State/Province | Massachusetts | - | Pennsylvania | North Carolina | Massachusetts |
| No. of Employees | 85 | 249 | 132 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Stack | Chairman | Executive Board | 2014 | - |
| Raj Kannan | Director; Chief Executive Officer; President | Executive Board | 2019 | - |
| John Doyle | Chief Financial Officer | Senior Management | - | - |
| William Ludlam | Senior Vice President - Clinical Development and Medical Affairs | Senior Management | 2015 | - |
| Lee Giguere | General Counsel; Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer